Cargando…

Clinical outcomes of deferred revascularisation using fractional flow reserve in patients with and without diabetes mellitus

OBJECTIVE: Deferred revascularisation based upon fractional flow reserve (FFR >0.80) is associated with a low incidence of target lesion failure (TLF). Whether deferred revascularisation is also as safe in diabetes mellitus (DM) patients is unknown. METHODS: All DM patients and the next consecuti...

Descripción completa

Detalles Bibliográficos
Autores principales: Kennedy, Mark W., Kaplan, Eliza, Hermanides, Rik S., Fabris, Enrico, Hemradj, Veemal, Koopmans, Petra C., Dambrink, Jan-Hank E., Marcel Gosselink, A. T., van‘t Hof, Arnoud W. J., Ottervanger, Jan Paul, Roolvink, Vincent, Remkes, Wouter S., van der Sluis, Aize, Suryapranata, Harry, Kedhi, Elvin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950234/
https://www.ncbi.nlm.nih.gov/pubmed/27431395
http://dx.doi.org/10.1186/s12933-016-0417-2
_version_ 1782443545212223488
author Kennedy, Mark W.
Kaplan, Eliza
Hermanides, Rik S.
Fabris, Enrico
Hemradj, Veemal
Koopmans, Petra C.
Dambrink, Jan-Hank E.
Marcel Gosselink, A. T.
van‘t Hof, Arnoud W. J.
Ottervanger, Jan Paul
Roolvink, Vincent
Remkes, Wouter S.
van der Sluis, Aize
Suryapranata, Harry
Kedhi, Elvin
author_facet Kennedy, Mark W.
Kaplan, Eliza
Hermanides, Rik S.
Fabris, Enrico
Hemradj, Veemal
Koopmans, Petra C.
Dambrink, Jan-Hank E.
Marcel Gosselink, A. T.
van‘t Hof, Arnoud W. J.
Ottervanger, Jan Paul
Roolvink, Vincent
Remkes, Wouter S.
van der Sluis, Aize
Suryapranata, Harry
Kedhi, Elvin
author_sort Kennedy, Mark W.
collection PubMed
description OBJECTIVE: Deferred revascularisation based upon fractional flow reserve (FFR >0.80) is associated with a low incidence of target lesion failure (TLF). Whether deferred revascularisation is also as safe in diabetes mellitus (DM) patients is unknown. METHODS: All DM patients and the next consecutive Non-DM patients who underwent a FFR-assessment between 1/01/2010 and 31/12/2013 were included, and followed until 1/07/2015. Patients with lesions FFR >0.80 were analysed according to the presence vs. absence of DM, while patients who underwent index revascularisation in FFR-assessed or other lesions were excluded. The primary endpoint was the incidence of TLF; a composite of target lesion revascularisation (TLR) and target vessel myocardial infarction (TVMI). RESULTS: A total of 250 patients (122 DM, 128 non-DM) who underwent deferred revascularisation of all lesions (FFR >0.80) were compared. At a mean follow up of 39.8 ± 16.3 months, DM patients compared to non-DM had a higher TLF rate, 18.1 vs 7.5 %, logrank p ≤ 0.01, Cox regression-adjusted HR 3.65 (95 % CI 1.40–9.53, p < 0.01), which was largely driven by a higher incidence of TLR (17.2 vs. 7.5 %, HR 3.52, 95 % CI 1.34–9.30, p = 0.01), whilst a non-significant but numerically higher incidence of TVMI (6.1 vs. 2.0 %, HR 3.34, 95 % CI 0.64–17.30, p = 0.15) was observed. CONCLUSIONS: This study, the largest to directly compare the clinical outcomes of FFR-guided deferred revascularisation in patients with and without DM, shows that DM patients are associated with a significantly higher TLF rate. Whether intravascular imaging, additional invasive haemodynamics or stringent risk factor modification may impact on this higher TLF rate remains unknown.
format Online
Article
Text
id pubmed-4950234
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49502342016-07-20 Clinical outcomes of deferred revascularisation using fractional flow reserve in patients with and without diabetes mellitus Kennedy, Mark W. Kaplan, Eliza Hermanides, Rik S. Fabris, Enrico Hemradj, Veemal Koopmans, Petra C. Dambrink, Jan-Hank E. Marcel Gosselink, A. T. van‘t Hof, Arnoud W. J. Ottervanger, Jan Paul Roolvink, Vincent Remkes, Wouter S. van der Sluis, Aize Suryapranata, Harry Kedhi, Elvin Cardiovasc Diabetol Original Investigation OBJECTIVE: Deferred revascularisation based upon fractional flow reserve (FFR >0.80) is associated with a low incidence of target lesion failure (TLF). Whether deferred revascularisation is also as safe in diabetes mellitus (DM) patients is unknown. METHODS: All DM patients and the next consecutive Non-DM patients who underwent a FFR-assessment between 1/01/2010 and 31/12/2013 were included, and followed until 1/07/2015. Patients with lesions FFR >0.80 were analysed according to the presence vs. absence of DM, while patients who underwent index revascularisation in FFR-assessed or other lesions were excluded. The primary endpoint was the incidence of TLF; a composite of target lesion revascularisation (TLR) and target vessel myocardial infarction (TVMI). RESULTS: A total of 250 patients (122 DM, 128 non-DM) who underwent deferred revascularisation of all lesions (FFR >0.80) were compared. At a mean follow up of 39.8 ± 16.3 months, DM patients compared to non-DM had a higher TLF rate, 18.1 vs 7.5 %, logrank p ≤ 0.01, Cox regression-adjusted HR 3.65 (95 % CI 1.40–9.53, p < 0.01), which was largely driven by a higher incidence of TLR (17.2 vs. 7.5 %, HR 3.52, 95 % CI 1.34–9.30, p = 0.01), whilst a non-significant but numerically higher incidence of TVMI (6.1 vs. 2.0 %, HR 3.34, 95 % CI 0.64–17.30, p = 0.15) was observed. CONCLUSIONS: This study, the largest to directly compare the clinical outcomes of FFR-guided deferred revascularisation in patients with and without DM, shows that DM patients are associated with a significantly higher TLF rate. Whether intravascular imaging, additional invasive haemodynamics or stringent risk factor modification may impact on this higher TLF rate remains unknown. BioMed Central 2016-07-19 /pmc/articles/PMC4950234/ /pubmed/27431395 http://dx.doi.org/10.1186/s12933-016-0417-2 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Original Investigation
Kennedy, Mark W.
Kaplan, Eliza
Hermanides, Rik S.
Fabris, Enrico
Hemradj, Veemal
Koopmans, Petra C.
Dambrink, Jan-Hank E.
Marcel Gosselink, A. T.
van‘t Hof, Arnoud W. J.
Ottervanger, Jan Paul
Roolvink, Vincent
Remkes, Wouter S.
van der Sluis, Aize
Suryapranata, Harry
Kedhi, Elvin
Clinical outcomes of deferred revascularisation using fractional flow reserve in patients with and without diabetes mellitus
title Clinical outcomes of deferred revascularisation using fractional flow reserve in patients with and without diabetes mellitus
title_full Clinical outcomes of deferred revascularisation using fractional flow reserve in patients with and without diabetes mellitus
title_fullStr Clinical outcomes of deferred revascularisation using fractional flow reserve in patients with and without diabetes mellitus
title_full_unstemmed Clinical outcomes of deferred revascularisation using fractional flow reserve in patients with and without diabetes mellitus
title_short Clinical outcomes of deferred revascularisation using fractional flow reserve in patients with and without diabetes mellitus
title_sort clinical outcomes of deferred revascularisation using fractional flow reserve in patients with and without diabetes mellitus
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950234/
https://www.ncbi.nlm.nih.gov/pubmed/27431395
http://dx.doi.org/10.1186/s12933-016-0417-2
work_keys_str_mv AT kennedymarkw clinicaloutcomesofdeferredrevascularisationusingfractionalflowreserveinpatientswithandwithoutdiabetesmellitus
AT kaplaneliza clinicaloutcomesofdeferredrevascularisationusingfractionalflowreserveinpatientswithandwithoutdiabetesmellitus
AT hermanidesriks clinicaloutcomesofdeferredrevascularisationusingfractionalflowreserveinpatientswithandwithoutdiabetesmellitus
AT fabrisenrico clinicaloutcomesofdeferredrevascularisationusingfractionalflowreserveinpatientswithandwithoutdiabetesmellitus
AT hemradjveemal clinicaloutcomesofdeferredrevascularisationusingfractionalflowreserveinpatientswithandwithoutdiabetesmellitus
AT koopmanspetrac clinicaloutcomesofdeferredrevascularisationusingfractionalflowreserveinpatientswithandwithoutdiabetesmellitus
AT dambrinkjanhanke clinicaloutcomesofdeferredrevascularisationusingfractionalflowreserveinpatientswithandwithoutdiabetesmellitus
AT marcelgosselinkat clinicaloutcomesofdeferredrevascularisationusingfractionalflowreserveinpatientswithandwithoutdiabetesmellitus
AT vanthofarnoudwj clinicaloutcomesofdeferredrevascularisationusingfractionalflowreserveinpatientswithandwithoutdiabetesmellitus
AT ottervangerjanpaul clinicaloutcomesofdeferredrevascularisationusingfractionalflowreserveinpatientswithandwithoutdiabetesmellitus
AT roolvinkvincent clinicaloutcomesofdeferredrevascularisationusingfractionalflowreserveinpatientswithandwithoutdiabetesmellitus
AT remkeswouters clinicaloutcomesofdeferredrevascularisationusingfractionalflowreserveinpatientswithandwithoutdiabetesmellitus
AT vandersluisaize clinicaloutcomesofdeferredrevascularisationusingfractionalflowreserveinpatientswithandwithoutdiabetesmellitus
AT suryapranataharry clinicaloutcomesofdeferredrevascularisationusingfractionalflowreserveinpatientswithandwithoutdiabetesmellitus
AT kedhielvin clinicaloutcomesofdeferredrevascularisationusingfractionalflowreserveinpatientswithandwithoutdiabetesmellitus